• Mutation; HGNC; HGNC:914; B2M; Simple; p.Asp96Metfs*6 (c.286delG); Zygosity=Unspecified (PubMed=8432869).
  

PubMed=1067619; DOI=10.1073/pnas.73.9.3278; PMCID=PMC431008
Thomas E. Carey, Toshitada Takahashi, Lois A. Resnick-Silverman, Herbert Friedrich Oettgen, Lloyd John Old;
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976)

PubMed=6933476; DOI=10.1073/pnas.77.7.4260; PMCID=PMC349812
Alan N. Houghton, Michael C. Taormina, Hisami Ikeda, Tadashi Watanabe, Herbert Friedrich Oettgen, Lloyd John Old;
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980)

DOI=10.1007/978-1-4615-7228-2_39
Alan N. Houghton, Herbert Friedrich Oettgen, Lloyd John Old;
Malignant melanoma. Current status of the search for melanoma-specific antigens.
(In book chapter) Immunodermatology. Comprehensive Immunology, Vol 7; Safai, Bijan & Good, Robert Alan (eds.); pp.557-576; Springer; Boston; USA (1981)

PubMed=6864164; DOI=10.1084/jem.158.1.53; PMCID=PMC2187084
Alan N. Houghton, Hannah Brooks, Richard J. Cote, Michael C. Taormina, Herbert Friedrich Oettgen, Lloyd John Old;
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
J. Exp. Med. 158:53-65(1983)

PubMed=2983346; DOI=10.1073/pnas.82.5.1470; PMCID=PMC397284
Nicholas C. Dracopoli, Alan N. Houghton, Lloyd John Old;
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity.
Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985)

PubMed=3518877; DOI=10.3109/07357908609038260
Jorgen Fogh;
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=8432869; DOI=10.1172/JCI116249; PMCID=PMC288010
Z. Wang, Y. Cao, Anthony P. Albino, Richard A. Zeff, Alan N. Houghton, Soldano Ferrone;
Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA.
J. Clin. Invest. 91:684-692(1993)